Pretražite po imenu i prezimenu autora, mentora, urednika, prevoditelja

Napredna pretraga

Pregled bibliografske jedinice broj: 1106859

COVID-19 and hypertension: is the HSP60 culprit for the severe course and worse outcome?


Jakovac, Hrvoje
COVID-19 and hypertension: is the HSP60 culprit for the severe course and worse outcome? // American journal of physiology. Heart and circulatory physiology, 319 (2020), 4; H793-H796 doi:10.1152/ajpheart.00506.2020 (međunarodna recenzija, članak, znanstveni)


CROSBI ID: 1106859 Za ispravke kontaktirajte CROSBI podršku putem web obrasca

Naslov
COVID-19 and hypertension: is the HSP60 culprit for the severe course and worse outcome?
(COVID-19 and hypertension: is the HSP60 culprit for the severe course and worse outcome?)

Autori
Jakovac, Hrvoje

Izvornik
American journal of physiology. Heart and circulatory physiology (0363-6135) 319 (2020), 4; H793-H796

Vrsta, podvrsta i kategorija rada
Radovi u časopisima, članak, znanstveni

Ključne riječi
COVID-19 ; HSP60 ; hypertension ; mizoribine ; SARS-CoV-2 ; severity

Sažetak
COVID-19 and hypertension: is the HSP60 culprit for the severe course and worse outcome? Am J Physiol Heart Circ Physiol 319: H793–H796, 2020. First published September 4, 2020 ; doi:10.1152/ajpheart.00506.2020.—The 60-kDa heat shock protein (HSP60) is a chaperone essential for mitochondrial proteostasis ensuring thus sufficient aerobic energy production. In pathological conditions, HSP60 can be translocated from the mitochondria and excreted from the cell. In turn, the extracellular HSP60 has a strong ability to trigger and enhance inflammatory response with marked proinflammatory cytokine induction, which is mainly mediated by Toll-like receptor binding. Previous studies have found increased circulating levels of HSP60 in hypertensive patients, as well as enhanced HSP60 expression and membrane translocation in the hypertrophic myocardium. These observations are of particular interest, since they could provide a possible pathophysiological explanation of the severe course and worse outcome of severe acute respiratory syndrome coronavirus 2 infection in hypertensive patients, repeatedly reported during the recent coronavirus disease 2019 (COVID-19) pandemic and related to hyperinflammatory response and cytokine storm development during the third phase of the disease. In this regard, pharmacological inhibition of HSP60 could attract attention to potentially ameliorate inappropriate inflammatory reaction in severe COVID-19 patients. Among HSP60 antagonizing drugs, mizoribine is the most intriguing, since it is clinically approved and exerts antiviral activity. However, this topic requires to be further scrutinized.

Izvorni jezik
Engleski

Znanstvena područja
Temeljne medicinske znanosti



POVEZANOST RADA


Ustanove:
Medicinski fakultet, Rijeka

Profili:

Avatar Url Hrvoje Jakovac (autor)

Poveznice na cjeloviti tekst rada:

doi journals.physiology.org

Citiraj ovu publikaciju:

Jakovac, Hrvoje
COVID-19 and hypertension: is the HSP60 culprit for the severe course and worse outcome? // American journal of physiology. Heart and circulatory physiology, 319 (2020), 4; H793-H796 doi:10.1152/ajpheart.00506.2020 (međunarodna recenzija, članak, znanstveni)
Jakovac, H. (2020) COVID-19 and hypertension: is the HSP60 culprit for the severe course and worse outcome?. American journal of physiology. Heart and circulatory physiology, 319 (4), H793-H796 doi:10.1152/ajpheart.00506.2020.
@article{article, author = {Jakovac, Hrvoje}, year = {2020}, pages = {H793-H796}, DOI = {10.1152/ajpheart.00506.2020}, keywords = {COVID-19, HSP60, hypertension, mizoribine, SARS-CoV-2, severity}, journal = {American journal of physiology. Heart and circulatory physiology}, doi = {10.1152/ajpheart.00506.2020}, volume = {319}, number = {4}, issn = {0363-6135}, title = {COVID-19 and hypertension: is the HSP60 culprit for the severe course and worse outcome?}, keyword = {COVID-19, HSP60, hypertension, mizoribine, SARS-CoV-2, severity} }
@article{article, author = {Jakovac, Hrvoje}, year = {2020}, pages = {H793-H796}, DOI = {10.1152/ajpheart.00506.2020}, keywords = {COVID-19, HSP60, hypertension, mizoribine, SARS-CoV-2, severity}, journal = {American journal of physiology. Heart and circulatory physiology}, doi = {10.1152/ajpheart.00506.2020}, volume = {319}, number = {4}, issn = {0363-6135}, title = {COVID-19 and hypertension: is the HSP60 culprit for the severe course and worse outcome?}, keyword = {COVID-19, HSP60, hypertension, mizoribine, SARS-CoV-2, severity} }

Časopis indeksira:


  • Current Contents Connect (CCC)
  • Web of Science Core Collection (WoSCC)
    • Science Citation Index Expanded (SCI-EXP)
    • SCI-EXP, SSCI i/ili A&HCI
  • Scopus
  • MEDLINE


Citati:





    Contrast
    Increase Font
    Decrease Font
    Dyslexic Font